Background: Several bleeding risk assessment models have been developed in atrial
fibrillation (AF) patients with oral anticoagulants, but the most appropriate tool for predicting …

BACKGROUND: Patients with atrial fibrillation (AF) and frailty are a considerable group in
clinical practice. However, existing studies provide insufficient evidence of anticoagulation …

Background In patients with atrial fibrillation who survive an anticoagulation-associated
intracerebral haemorrhage, a decision must be made as to whether restarting or …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …

Background and Objectives Ischemic stroke despite a direct oral anticoagulant (DOAC) is
increasingly common and portends a high risk of subsequent ischemic stroke. The efficacy …

To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke
in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by …

Abstract Background and Objective Drug–drug interactions between direct oral
anticoagulants (DOAC) and antiseizure medications via the cytochrome P450 (CYP) or the P …

Background: The use of direct oral anticoagulants (DOACs) is recommended as the
preferred treatment drug in patients with nonvalvular atrial fibrillation (AF). However, the …

Background Direct oral anticoagulants (DOACs) and warfarin are usually used for people
with atrial fibrillation (AF). However, for the AF patients at risk of falling, the effectiveness and …

Background: The cardiovascular protection effect of metformin on patients with type 2
diabetes mellitus (T2DM) remains inconclusive. This systemic review and meta-analysis …